These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8846240)

  • 1. Cost-effectiveness of autologous bone marrow transplantation.
    Lawless GD
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S11-4. PubMed ID: 8846240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
    J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer.
    Kennedy MJ; Davis J; Passos-Coelho J; Noga SJ; Huelskamp AM; Ohly K; Davidson NE
    Cancer Res; 1993 Nov; 53(22):5424-8. PubMed ID: 7693341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
    Stahel RA; Jost LM; Cerny T; Pichert G; Honegger H; Tobler A; Jacky E; Fey M; Platzer E
    J Clin Oncol; 1994 Sep; 12(9):1931-8. PubMed ID: 7521907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
    Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation.
    Uyl-de Groot CA; Richel DJ; Rutten FF
    Eur J Cancer; 1994; 30A(11):1631-5. PubMed ID: 7530471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma.
    Uyl-de Groot CA; Ossenkoppele GJ; Buijt I; Huijgens PC
    Pharmacoeconomics; 1999 Mar; 15(3):305-11. PubMed ID: 10537437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit.
    McQuaker IG; Hunter AE; Pacey S; Haynes AP; Iqbal A; Russell NH
    J Clin Oncol; 1997 Feb; 15(2):451-7. PubMed ID: 9053465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia.
    Demirer T; Buckner CD; Appelbaum FR; Petersen FB; Rowley S; Weaver CH; Lilleby K; Sanders J; Chauncey T; Storb R
    Bone Marrow Transplant; 1995 Jun; 15(6):915-22. PubMed ID: 7581091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial.
    Hartmann O; Le Corroller AG; Blaise D; Michon J; Philip I; Norol F; Janvier M; Pico JL; Baranzelli MC; Rubie H; Coze C; Pinna A; Méresse V; Benhamou E
    Ann Intern Med; 1997 Apr; 126(8):600-7. PubMed ID: 9103126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow.
    Schriber JR; Negrin RS; Chao NJ; Long GD; Horning SJ; Blume KG
    Leukemia; 1993 Oct; 7(10):1491-5. PubMed ID: 7692189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engraftment with peripheral blood stem cells using noncontrolled-rate cryopreservation: comparison with autologous bone marrow transplantation.
    Rosenfeld CS; Gremba C; Shadduck RK; Zeigler ZR; Nemunaitis J
    Exp Hematol; 1994 Mar; 22(3):290-4. PubMed ID: 7509292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery.
    Ianotto JC; Ngo Sack F; Couturier MA; Tempescul A; Mugnier N; Delepine P; Guillerm G; Berthou C
    Leuk Lymphoma; 2014 Jan; 55(1):74-7. PubMed ID: 23566160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).
    Sebban C; Lefranc A; Perrier L; Moreau P; Espinouse D; Schmidt A; Kammoun L; Ghesquieres H; Ferlay C; Bay JO; Lissandre S; Pérol D; Michallet M; Quittet P
    Eur J Cancer; 2012 Mar; 48(5):713-20. PubMed ID: 22248711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health resource utilization in ABMT with and without G-CSF in stage III/IV breast cancer patients.
    Lawless GD; D'Amico F; Galli T; Garty MK
    Oncology (Williston Park); 1995 Nov; 9(11 Suppl):107-10. PubMed ID: 8608039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effective use of autologous bone marrow transplantation: few answers, many questions, and suggestions for future assessments.
    Hillner BE; Smith TJ; Desch CE
    Pharmacoeconomics; 1994 Aug; 6(2):114-26. PubMed ID: 10147437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
    Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
    Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation.
    Souêtre E; Qing W; Pénelaud PF
    Eur J Cancer; 1996 Jun; 32A(7):1162-5. PubMed ID: 8758247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of recombinant human granulocyte colony-stimulating factor in children undergoing bone marrow transplantation.
    Dini G; Floris R; Pession A; Manfredini L; Dallorso S; Lanino E; Garaventa A; Miano M; Kotitsa Z; Rondelli R
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():121-8. PubMed ID: 8932813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas.
    Stahel RA; Jost LM; Honegger H; Betts E; Goebel ME; Nagler A
    J Clin Oncol; 1997 May; 15(5):1730-5. PubMed ID: 9164179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.